$NBIX
NEUROCRINE BIOSCIENCES INC

2016 Form 10-K Financial Statement

#000119312517043838 Filed on February 14, 2017

View on sec.gov

Income Statement

Concept 2016 2015 Q4 2015 Q3
Revenue $15.00M $0.00 $0.00
YoY Change -24.12%
Cost Of Revenue $0.00
YoY Change
Gross Profit $15.00M
YoY Change -24.12%
Gross Profit Margin 100.0%
Selling, General & Admin $68.08M $8.900M $11.50M
YoY Change 109.61% 78.0% 144.68%
% of Gross Profit 453.87%
Research & Development $94.29M $21.80M $24.39M
YoY Change 15.71% 40.65% 100.0%
% of Gross Profit 628.61%
Depreciation & Amortization $1.500M $300.0K $200.0K
YoY Change 50.0% 50.0% 0.0%
% of Gross Profit 10.0%
Operating Expenses $162.4M $30.75M $35.84M
YoY Change 42.47% 50.22% 112.64%
Operating Profit -$147.4M -$35.84M
YoY Change 56.44% 112.64%
Interest Expense $0.00 $600.0K $600.0K
YoY Change 200.0% 200.0%
% of Operating Profit
Other Income/Expense, Net $6.282M $800.0K $1.409M
YoY Change 19.14% 0.0% 43.48%
Pretax Income -$141.1M -$29.30M -$34.40M
YoY Change 58.71% 51.03% 116.35%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$141.1M -$29.32M -$34.44M
YoY Change 58.65% 50.77% 116.91%
Net Earnings / Revenue -940.6%
Basic Earnings Per Share -$1.63
Diluted Earnings Per Share -$1.63 -$339.9K -$400.5K
COMMON SHARES
Basic Shares Outstanding 86.71M 86.20M shares 85.87M shares
Diluted Shares Outstanding 86.71M

Balance Sheet

Concept 2016 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $307.4M $379.2M $376.8M
YoY Change -18.93% 95.67% 109.68%
Cash & Equivalents $83.30M $74.20M $66.38M
Short-Term Investments $224.1M $305.0M $310.5M
Other Short-Term Assets $3.100M $4.883M $5.940M
YoY Change -36.73% 11.13% 41.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $310.4M $384.1M $382.8M
YoY Change -19.19% 93.78% 108.18%
LONG-TERM ASSETS
Property, Plant & Equipment $6.300M $3.432M $2.874M
YoY Change 85.29% 36.9% 25.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $43.50M $82.50M $102.0M
YoY Change -47.27% 120.0% 52.01%
Other Assets $4.900M $4.800M $4.800M
YoY Change 2.08% 0.0% 9.09%
Total Long-Term Assets $54.70M $90.71M $109.7M
YoY Change -39.69% 102.34% 48.41%
TOTAL ASSETS
Total Short-Term Assets $310.4M $384.1M $382.8M
Total Long-Term Assets $54.70M $90.71M $109.7M
Total Assets $365.1M $474.8M $492.4M
YoY Change -23.1% 95.36% 91.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.100M $2.561M $1.197M
YoY Change 96.15% 941.06% 33.0%
Accrued Expenses $21.10M $19.03M $14.51M
YoY Change 11.05% 65.4% 55.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.40M $25.72M $19.82M
YoY Change 18.29% 64.17% 41.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.80M $221.0K $220.0K
YoY Change -19.51% -15.0% -15.38%
Total Long-Term Liabilities $19.80M $221.0K $220.0K
YoY Change -19.51% -15.0% -15.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.40M $25.72M $19.82M
Total Long-Term Liabilities $19.80M $221.0K $220.0K
Total Liabilities $50.20M $50.33M $45.49M
YoY Change -0.2% 46.59% 34.94%
SHAREHOLDERS EQUITY
Retained Earnings -$915.2M -$885.9M
YoY Change 10.76% 9.8%
Common Stock $1.341B $1.333B
YoY Change 29.5% 1754467.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $314.9M $424.5M $446.9M
YoY Change
Total Liabilities & Shareholders Equity $365.1M $474.8M $492.4M
YoY Change -23.1% 95.36% 91.05%

Cashflow Statement

Concept 2016 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$141.1M -$29.32M -$34.44M
YoY Change 58.65% 50.77% 116.91%
Depreciation, Depletion And Amortization $1.500M $300.0K $200.0K
YoY Change 50.0% 50.0% 0.0%
Cash From Operating Activities -$106.2M -$15.20M -$18.60M
YoY Change 179.42% -0.65% 53.72%
INVESTING ACTIVITIES
Capital Expenditures $4.108M -$800.0K -$300.0K
YoY Change 112.41% 100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $117.1M $22.90M -$47.60M
YoY Change -160.39% 44.03% -1460.0%
Cash From Investing Activities $113.0M $22.10M -$47.90M
YoY Change -157.69% 42.58% -1596.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.390M
YoY Change -99.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.390M 1.000M 700.0K
YoY Change -99.14% -41.18% 40.0%
NET CHANGE
Cash From Operating Activities -106.2M -15.20M -18.60M
Cash From Investing Activities 113.0M 22.10M -47.90M
Cash From Financing Activities 2.390M 1.000M 700.0K
Net Change In Cash 9.164M 7.900M -65.80M
YoY Change -78.79% 315.79% 683.33%
FREE CASH FLOW
Cash From Operating Activities -$106.2M -$15.20M -$18.60M
Capital Expenditures $4.108M -$800.0K -$300.0K
Free Cash Flow -$110.3M -$14.40M -$18.30M
YoY Change 176.18% -3.36% 55.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87114340 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
2868066028
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5853000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.54
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23131000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
120410000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5750000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23854000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
208699000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2014Q4 nbix Cease Use Liability
CeaseUseLiability
2678000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5507000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.63
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25715000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7358000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26861000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19034000
CY2015Q4 us-gaap Liabilities
Liabilities
50331000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
269000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1340579000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
33074000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-977000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
382400000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4317000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915234000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1711000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
424454000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
474785000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
387484000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4791000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
10900000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3432000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
384074000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4883000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4300000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3900000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
364070000
CY2015Q4 us-gaap Investments
Investments
387500000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
959000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6900000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74195000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction
DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction
5000000
CY2015Q4 us-gaap Assets
Assets
474785000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
82488000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
382400000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
22000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
400000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
257900000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
5521000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30293000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
981000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
304996000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
358549000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
33500000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7359000
CY2015Q4 nbix Deferred Tax Assets Lease Termination Charges
DeferredTaxAssetsLeaseTerminationCharges
700000
CY2015Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
58900000
CY2015Q4 nbix Cease Use Liability
CeaseUseLiability
1983000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
10898000
CY2015Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
1555000
CY2015Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
428000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3423000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6112000 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6700000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.55
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86883300 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4500000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86883300 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30414000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9559000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25950000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
7834000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21097000
CY2016Q4 us-gaap Liabilities
Liabilities
50209000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
470000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
87000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1371432000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
34112000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
8070000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-318000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
24215000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
463500000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
27400000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5995000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8311000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1056324000
CY2016Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
10900000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1462000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
314877000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365086000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5085000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
267573000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4883000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
17400000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6271000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
310442000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3092000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4300000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4400000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
251100000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
119900000
CY2016Q4 us-gaap Investments
Investments
267600000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
321000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4800000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
110200000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83267000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction
DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction
3800000
CY2016Q4 us-gaap Assets
Assets
365086000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
43490000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
463500000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
400000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
309100000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
9144000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32221000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
324000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
224083000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
241956000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
38800000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2016Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5543000
CY2016Q4 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2016Q4 nbix Cash And Investments Required To Be Maintained
CashAndInvestmentsRequiredToBeMaintained
50000000
CY2016Q4 nbix Number Of Subsidiaries Held
NumberOfSubsidiariesHeld
2 Subsidiary
CY2016Q4 nbix Deferred Tax Assets Lease Termination Charges
DeferredTaxAssetsLeaseTerminationCharges
300000
CY2016Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
80200000
CY2016Q4 nbix Cease Use Liability
CeaseUseLiability
853000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
7372000
CY2016Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
617000
CY2016Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
236000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3526000
CY2016Q4 nbix Potential Milestone Payments
PotentialMilestonePayments
17000000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133200000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1089000 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
57000 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.41
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74577000 shares
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47140000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
56.83
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.50
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1135000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.57
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74577000 shares
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2014 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60824000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1612000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3792000
CY2014 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3222000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
133171000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10382000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18000
CY2014 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
257544000
CY2014 us-gaap Licenses Revenue
LicensesRevenue
0
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1882000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-64411000
CY2014 us-gaap Revenues
Revenues
0
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
676000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
388000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
629000
CY2014 us-gaap Investment Income Net
InvestmentIncomeNet
629000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3869000
CY2014 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
1671000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5560000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
47000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-60542000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-282000
CY2014 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
3200000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138731000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
827000
CY2014 us-gaap Operating Expenses
OperatingExpenses
64411000
CY2014 us-gaap Depreciation
Depreciation
800000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
10000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138731000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-21190000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
14000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3410000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
79000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17986000
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3698000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14300000
CY2014 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13775000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6000000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25366000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10382000
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
10382000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
91000
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
154133000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-105366000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5600000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46425000
CY2014 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
621000
CY2014 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
3226000
CY2014 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
315000
CY2014 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
0
CY2014 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-418000
CY2014 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
-4000
CY2014 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
-4000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1159000 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4100000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87000 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.21
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84496000 shares
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37997000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
46.08
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.01
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1315000 shares
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.24
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84496000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84496000 shares
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2015 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89629000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5273000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-700000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6638000
CY2015 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
489000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-94202000
CY2015 us-gaap Revenues
Revenues
19769000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2584000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-40000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
1928000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
1928000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6304000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6636000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-88929000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1934000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-6032000
CY2015 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3334000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
270687000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28392000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
449052000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
19769000
CY2015 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
3300000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
276992000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1009000
CY2015 us-gaap Operating Expenses
OperatingExpenses
113971000
CY2015 us-gaap Depreciation
Depreciation
1000000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
276992000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-31126000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
172000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-16000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32480000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
53000
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9841000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
43600000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10773000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
43181000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6000000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15029000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28392000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-39000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
28392000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
201000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
255123000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-195814000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6300000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81491000
CY2015 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
5940000
CY2015 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
3325000
CY2015 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
5594000
CY2015 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
610000
CY2015 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-85000
CY2015 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-610000
CY2015 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-85000
CY2015 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
9000
CY2015 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
9000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Trading Symbol
TradingSymbol
NBIX
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1077000 shares
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3800000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
131000 shares
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk.</i></b>&#xA0;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity.</font></p> </div>
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
40.19
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86713000 shares
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60 pure
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-106181000
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.35
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.60
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
341000 shares
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates.</i></b>&#xA0;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86713000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2016 us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.49
CY2016 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28464000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86713000 shares
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2016 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-140431000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4108000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3520000
CY2016 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3431000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
298776000
CY2016 us-gaap Licenses Revenue
LicensesRevenue
15000000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6511000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-147372000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2016 us-gaap Revenues
Revenues
15000000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2211000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
92000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
2838000
CY2016 us-gaap Investment Income Net
InvestmentIncomeNet
2838000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6282000
CY2016 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-1791000
CY2016 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2390000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
260000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-141090000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
659000
CY2016 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
3400000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2390000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1453000
CY2016 us-gaap Operating Expenses
OperatingExpenses
162372000
CY2016 us-gaap Depreciation
Depreciation
1500000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-321000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2390000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-49383000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-294000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
68081000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
211000
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1433000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4398000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13200000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9072000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6000000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
53414000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28464000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-108000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
28464000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-5077000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
415826000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
112863000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2400000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94291000
CY2016 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
957000
CY2016 nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
CY2016 nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
CY2016 nbix Potential Increase In Security Deposits
PotentialIncreaseInSecurityDeposits
5000000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
41828000
CY2016 nbix Revenue From Pharmaceutical Products
RevenueFromPharmaceuticalProducts
0
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80349000 shares
CY2015Q1 us-gaap Revenues
Revenues
19769000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1192000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
22057000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85518000 shares
CY2016 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
3423000
CY2016 nbix Percentage Of Uncertain Tax Positions Likelihood Of Being Sustained
PercentageOfUncertainTaxPositionsLikelihoodOfBeingSustained
0.50 pure
CY2016 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
6708000
CY2016 nbix Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedForfeitureRate
0.00 pure
CY2016 nbix Operating Lease Expiration Year
OperatingLeaseExpirationYear
2019
CY2016 nbix Lease Expiration Year
LeaseExpirationYear
2019
CY2016 nbix Operating Lease Term
OperatingLeaseTerm
P12Y
CY2016 nbix Number Of Collaboration Agreements
NumberOfCollaborationAgreements
2 Agreement
CY2016 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
300000
CY2016 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-584000
CY2016 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-300000
CY2016 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-830000
CY2016 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
8000
CY2016 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
8000
CY2015Q2 us-gaap Revenues
Revenues
0
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23987000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
25322000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86497000 shares
CY2016Q1 us-gaap Revenues
Revenues
15000000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19264000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
35857000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86694000 shares
CY2016Q2 us-gaap Revenues
Revenues
0
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-40280000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85856000 shares
CY2015Q3 us-gaap Revenues
Revenues
0
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-34435000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
35844000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86784000 shares
CY2016Q3 us-gaap Revenues
Revenues
0
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-36887000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
38436000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86184000 shares
CY2015Q4 us-gaap Revenues
Revenues
0
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-29315000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
30748000
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86874000 shares
CY2016Q4 us-gaap Revenues
Revenues
0
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-44659000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
46251000

Files In Submission

Name View Source Status
0001193125-17-043838-index-headers.html Edgar Link pending
0001193125-17-043838-index.html Edgar Link pending
0001193125-17-043838.txt Edgar Link pending
0001193125-17-043838-xbrl.zip Edgar Link pending
d324435d10k.htm Edgar Link pending
d324435dex1019.htm Edgar Link pending
d324435dex1020.htm Edgar Link pending
d324435dex103.htm Edgar Link pending
d324435dex211.htm Edgar Link pending
d324435dex231.htm Edgar Link pending
d324435dex311.htm Edgar Link pending
d324435dex312.htm Edgar Link pending
d324435dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g324435g52p15.jpg Edgar Link pending
nbix-20161231.xml Edgar Link completed
nbix-20161231.xsd Edgar Link pending
nbix-20161231_cal.xml Edgar Link unprocessable
nbix-20161231_def.xml Edgar Link unprocessable
nbix-20161231_lab.xml Edgar Link unprocessable
nbix-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending